For research use only. Not for therapeutic Use.
SRD5A1-IN-1 (Compound 4) is a competitive and covalent steroid 5α-reductase type 1 (SRD5A1) inhibitor with an IC50 of 1.44 µM. SRD5A1-IN-1 modulates SRD5A1 function, leading to a lower level of dihydrotestosterone (DHT) production and SRD5A1 protein suppression[1].
SRD5A1-IN-1 (Compound 4) (0.5-2.5 μM; 24 h) decreases SRD5A1 protein expression[1].
SRD5A1-IN-1 (0-2.5 μM; 12 h) modulates SRD5A1 via the dual actions that affect the level of SRD5A1 protein expression and the activity of the SRD5A1 enzyme[1].
| Catalog Number | I042360 |
| CAS Number | 2279077-93-7 |
| Synonyms | (E)-N-[3,5-bis(trifluoromethyl)phenyl]-3-(3,4-dihydroxyphenyl)prop-2-enamide |
| Molecular Formula | C17H11F6NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H11F6NO3/c18-16(19,20)10-6-11(17(21,22)23)8-12(7-10)24-15(27)4-2-9-1-3-13(25)14(26)5-9/h1-8,25-26H,(H,24,27)/b4-2+ |
| InChIKey | VYSOCZLQZPSHHE-DUXPYHPUSA-N |
| SMILES | C1=CC(=C(C=C1C=CC(=O)NC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)O)O |
| Reference | [1]. Lin A C K, et al. Caffeic acid N-[3, 5-bis (trifluoromethyl) phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics. Scientific Reports, 2022, 12(1): 1-20. |
